Discussion {#s2}
==========

It was estimated that in 2015 there would be approximately 132,700 new cases of colorectal cancer and 49,700 deaths due to this disease \[[@B1]\]. While surgical resection of metastases is sometimes curative, most patients with liver metastases are not considered resectable because of the number or location of the metastases. Advances in the first-line treatment of metastatic colorectal cancer (mCRC), with increased response rates, can convert some patients with initially unresectable liver metastases to resectable, allowing for potentially curative treatment.

In the phase II OLIVIA trial, patients with liver metastases from mCRC were randomized to bevacizumab plus modified folinic acid, fluorouracil, and oxaliplatin (mFOLFOX6) or FOLFOXIRI \[[@B2]\]. Bevacizumab/FOLFOXIRI was associated with higher rates of response (81% vs. 62%) and resection (61% vs. 49%), and prolonged median progression-free survival (mPFS) (18.6 months vs. 11.5 months), compared with bevacizumab/mFOLFOX6. In the phase III TRIBE trial, first-line therapy with FOLFOXIRI/bevacizumab was associated with improved mPFS (12.1 months vs. 9.7 months) and response rate (65% vs. 53%) compared with FOLFIRI/bevacizumab; however, there was no difference in R0 resection rate between treatments (15% vs. 12%) \[[@B3]\]. A subsequent analysis showed significant improvement in median overall survival (OS) with FOLFOXIRI/bevacizumab treatment (29.8 months vs. 25.8 months) \[[@B4]\]. Another phase II study evaluated panitumumab with FOLFOXIRI as first-line treatment with wild-type KRAS, HRAS, NRAS, and BRAF mCRC \[[@B5]\]. Thirty-three patients (89%) achieved objective response. Sixteen patients (43%) underwent resection of metastatic sites, with R0 resection performed in 13 patients (35%).

Based on the potential for improved response rates, we conducted a phase II study of panitumumab plus FOLFOXIRI as first-line treatment for patients with wild-type KRAS mCRC with liver-only metastases. Patients were eligible regardless of whether they were considered surgical candidates at baseline. After the protocol was initiated, new findings were published indicating that RAS mutations outside of KRAS exon 2 are also associated with inferior survival with combination panitumumab and oxaliplatin-based therapy \[[@B6]\]. Enrollment was halted while patients in the study underwent expanded KRAS/NRAS analysis. Eight of the 15 patients consented to expanded analysis, with no additional mutations identified. Of the 12 patients evaluable for efficacy, 75% achieved a partial response (PR) ([Table 1](#T1){ref-type="table"}). Ten patients underwent surgery; all had complete resections that showed pathologic PR. No significant safety signals were seen; the most common treatment-related adverse events (all grades) were rash (80%), diarrhea (60%), fatigue (53%), and nausea (53%). Despite early closure of the study, this regimen is a viable option for patients with liver-only mCRC.

Trial Information {#s3}
=================

DiseaseColorectal cancerStage of disease / treatmentMetastatic / AdvancedPrior TherapyNoneType of study - 1Phase IIType of study - 2Single ArmPrimary EndpointOverall Response RateSecondary EndpointsRate of R0 resectionProgression-Free SurvivalAcute Toxicity Produced by the RegimenAdditional Details of Endpoints or Study DesignPlanned enrollment was originally 49 patients.Investigator\'s AnalysisActive and should be pursued further

Drug Information {#s4}
================

Drug 1Generic/Working namePanitumumabTrade nameVectibixCompany nameAmgenDrug typeAntibodyDrug classEpidermal growth factor receptorDose6 mg/kgRouteIVSchedule of AdministrationDay 1 of each 14-day cycle with FOLFOXIRI5-FU 3,200 mg/m^2^, 48-hour continuous IV infusionLeucovorin 200 mg/m^2^ IVIrinotecan 125 mg/m^2^Oxaliplatin 85 mg/m^2^ IV

Patient Characteristics {#s5}
=======================

Number of patients, male13Number of patients, female2StageIVAgeMedian (range): 55 (39--70)Number of prior systemic therapiesMedian (range): 0Performance Status: ECOG0 --- 121 --- 32 --- 03 --- 0Unknown --- 0OtherBaseline surgical candidate -- yes: 10 (67%)Baseline surgical candidate -- no: 5 (33%)Cancer Types or Histologic SubtypesAdenocarinoma, 15

Primary Assessment Method {#s6}
=========================

**Control Arm: Total Patient Population**Number of patients enrolled15Number of patients evaluable for toxicity15Number of patients evaluated for efficacy15Response assessment CR*n* = 0 (0%)Response assessment PR*n* = 9 (60%)Response assessment SD*n* = 3 (20%)Response assessment PD*n* = 0 (0%)Response assessment OTHER*n* = 3 (20%)(Median) duration assessment PFS13.3060 months, CI: 95%

Adverse Events {#s7}
==============

Assessment, Analysis, and Discussion {#s8}
====================================

CompletionStudy terminated before completionPharmacokinetics / PharmacodynamicsNot CollectedInvestigator\'s AssessmentActive and should be pursued further

It was estimated that in 2015 there would be approximately 132,700 new cases of colorectal cancer and 49,700 deaths due to this disease \[[@B1]\]. While surgical resection of metastases is sometimes curative, most patients with liver metastases are not considered resectable because of the number or location of the metastases. Advances in the first-line treatment of metastatic colorectal cancer (mCRC), with increased response rates, can convert some patients with initially unresectable liver metastases to resectable, allowing for potentially curative treatment.

In the phase II OLIVIA trial, patients with liver metastases from mCRC were randomized to bevacizumab plus modified folinic acid, fluorouracil, and oxaliplatin (mFOLFOX6) or FOLFOXIRI \[[@B2]\]. Bevacizumab/FOLFOXIRI was associated with higher rates of response (81% vs. 62%) and resection (61% vs. 49%), and prolonged median progression-free survival (mPFS) (18.6 months vs. 11.5 months), compared with bevacizumab/mFOLFOX6. In the phase III TRIBE trial, first-line therapy with FOLFOXIRI/bevacizumab was associated with improved mPFS (12.1 months vs. 9.7 months) and response rate (65% vs. 53%) compared with FOLFIRI/bevacizumab; however, there was no difference in R0 resection rate between treatments (15% vs. 12%) \[[@B3]\]. A subsequent analysis showed significant improvement in median overall survival (OS) with FOLFOXIRI/bevacizumab treatment (29.8 months vs. 25.8 months) \[[@B4]\]. Another phase II study evaluated panitumumab with FOLFOXIRI as first-line treatment with wild-type KRAS, HRAS, NRAS, and BRAF mCRC \[[@B5]\]. Thirty-three patients (89%) achieved objective response. Sixteen patients (43%) underwent resection of metastatic sites, with R0 resection performed in 13 patients (35%).

Based on the potential for improved response rates, we conducted a phase II study of panitumumab plus FOLFOXIRI as first-line treatment for patients with wild-type KRAS mCRC with liver-only metastases. Patients were eligible regardless of whether they were considered surgical candidates at baseline. After the protocol was initiated, new findings were published indicating that RAS mutations outside of KRAS exon 2 are also associated with inferior survival with combination panitumumab and oxaliplatin-based therapy \[[@B6]\]. Enrollment was halted while patients in the study underwent expanded KRAS/NRAS analysis. [Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} present PFS and OS data from our study. Eight of the 15 patients consented to expanded analysis, with no additional mutations identified. Of the 12 patients evaluable for efficacy, 75% achieved a partial response (PR) ([Table 1](#T1){ref-type="table"}). Ten patients underwent surgery; all had complete resections that showed pathologic PR. No significant safety signals were seen; the most common treatment-related adverse events (all grades) were rash (80%), diarrhea (60%), fatigue (53%), and nausea (53%) ([Table 2](#T2){ref-type="table"}). Despite early closure of the study, this regimen is a viable option for patients with liver-only mCRC.
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###### Data Set

[**ClinicalTrials.gov**](http://ClinicalTrials.gov) **Identifier:** [NCT01226719](http://clinicaltrials.gov/ct2/show/NCT01226719)

**Sponsor:** Sarah Cannon Research Institute

**Principal Investigator:** Johanna C. Bendell

**IRB Approved:** Yes

[Click here](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results) to access other published clinical trials.
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![Progression-free survival (*n* = 15).\
Abbreviations: CI, confidence interval; PFS, progression-free survival.](theoncologist_15439CTR_f1){#F1}

![Overall survival (*n* = 15).\
Abbreviations: CI, confidence interval; NR, not reached; OS, overall survival.](theoncologist_15439CTR_f2){#F2}
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Summary of clinical activities
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Treatment-related adverse events (*n* = 15 patients)
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